Literature DB >> 30859689

Pembrolizumab-associated ocular myasthenia gravis.

Qinqin Liu1, Sujith Ayyappan1, Adam Broad1, Andrew Narita1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30859689     DOI： 10.1111/ceo.13499

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN： 1442-6404            Impact factor:   4.207


× No keyword cloud information.
  2 in total

Review 1.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

2.  Association Between Clinical Factors and Result of Immune Checkpoint Inhibitor Related Myasthenia Gravis: A Single Center Experience and Systematic Review.

Authors:  Jiayu Shi; Ying Tan; Yangyu Huang; Ke Li; Jingwen Yan; Yuzhou Guan; Li Zhang
Journal:  Front Neurol       Date:  2022-04-07       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.